Gilead Sciences, Inc.
GILD
$114.43
-$2.78-2.37%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 28.75B | 28.30B | 27.80B | 27.45B | 27.12B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.75B | 28.30B | 27.80B | 27.45B | 27.12B |
| Cost of Revenue | 6.25B | 6.28B | 6.27B | 6.17B | 6.02B |
| Gross Profit | 22.50B | 22.02B | 21.53B | 21.28B | 21.10B |
| SG&A Expenses | 6.00B | 5.72B | 5.63B | 6.11B | 6.06B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.09B | 17.66B | 17.62B | 18.05B | 17.83B |
| Operating Income | 10.66B | 10.64B | 10.19B | 9.40B | 9.28B |
| Income Before Tax | 691.00M | 177.00M | 1.54B | 1.08B | 6.86B |
| Income Tax Expenses | 211.00M | 63.00M | 506.00M | 617.00M | 1.25B |
| Earnings from Continuing Operations | 480.00 | 114.00 | 1.03K | 458.00 | 5.61K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 12.00M | 20.00M | 26.00M | 52.00M |
| Net Income | 480.00M | 126.00M | 1.05B | 484.00M | 5.66B |
| EBIT | 10.66B | 10.64B | 10.19B | 9.40B | 9.28B |
| EBITDA | 13.43B | 13.40B | 12.94B | 12.15B | 11.98B |
| EPS Basic | 0.38 | 0.10 | 0.84 | 0.38 | 4.54 |
| Normalized Basic EPS | 5.00 | 5.00 | 4.80 | 4.44 | 4.40 |
| EPS Diluted | 0.35 | 0.08 | 0.81 | 0.35 | 4.49 |
| Normalized Diluted EPS | 4.97 | 4.98 | 4.78 | 4.42 | 4.37 |
| Average Basic Shares Outstanding | 4.99B | 4.99B | 4.99B | 4.99B | 4.99B |
| Average Diluted Shares Outstanding | 5.01B | 5.01B | 5.01B | 5.02B | 5.03B |
| Dividend Per Share | 3.08 | 3.06 | 3.04 | 3.02 | 3.00 |
| Payout Ratio | 816.25% | 3,085.71% | 366.38% | 791.32% | 67.25% |
